Michael Postow is a medical oncologist who cares exclusively for patients with advanced melanoma seeking discussions about systemic treatments. He is the Chief of the Melanoma Service at Memorial Sloan Kettering Cancer Center where he leads a group of six faculty physicians dedicated to the care and research of patients with melanoma. His prior work leading the first randomized trial of combined immune checkpoint inhibition (nivolumab + ipilimumab) resulted in its FDA approval in 2015, and he has led several other investigator-initiated trials of immunotherapy combinations. He enjoys skiing, outdoor activities, and as a Cincinnati native (Sycamore High School), burning off past Skyline chili meals by trying to keep up with his two toddlers and triathlete wife.